Veinstein Bar sold $542K of CLVT
Veinstein Bar (President, A&G) sold 254,558 shares of CLARIVATE PLC (CLVT) at $2.13 ($0.54M total) on 2026-11-18 under a Rule 10b5-1 trading plan.
CLARIVATE PLC
Clarivate provides intelligence solutions, workflow software and technology-enabled services to customers in academia and government, intellectual property, and life sciences and healthcare. Its customers include academic institutions and libraries, research organizations, corporations, law firms, government entities, and pharmaceutical, biotechnology, and medical device companies. Clarivate is headquartered in London, United Kingdom. Clarivate operates through three segments. Academia & Government offers research and learning products and services, including Web of Science, ProQuest, Alma, Vega and Polaris. Intellectual Property provides patent and trademark services, data and software, including Derwent, CompuMark, IPfolio and FoundationIP. Life Sciences & Healthcare offers research and development, commercial and medtech intelligence, including the Cortellis product suite. Clarivate earns money primarily through subscriptions and recurring contracts, including patent and trademark renewal services, as well as transactional sales of content, consulting and professional services.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Veinstein Bar (President, A&G) sold 254,558 shares of CLARIVATE PLC (CLVT) at $2.13 ($0.54M total) on 2026-11-18 under a Rule 10b5-1 trading plan.
Clarivate Plc (CLVT) reported a shift to AI-led, subscription-based products, aiming for 10%-15% FY 2027 free cash flow growth and debt reduction. Management targets margin maintenance while driving retention and new business growth, according to a conference transcript.
Clarivate (CLVT) integrated Derwent patent and Darts-ip litigation data into Claude via IPOne, adding to existing CompuMark trademark data. The move expands IP intelligence distribution, but no financial details or impact were disclosed.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CLVT (CLARIVATE PLC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent CLVT coverage spans earnings, financial news and corporate actions.
In the last 30 days, CLVT insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($542K). The most active reporter was Veinstein Bar, President, A&G, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
This is a routine 10b5-1 insider sale disclosure, typically viewed as neutral to mildly negative for near-term sentiment.
No new information; reiterates already‑public guidance.
The addition expands Clarivate's AI data services but no financial terms or revenue impact were disclosed.
The tender offer may pressure Clarivate's debt prices and could affect the stock as investors assess financing costs.
Goldman Sachs kept its Neutral rating on Clarivate but reduced its price target by 11.5% to $2.30, suggesting an 8.5% upside from the Nov 4 close of $2.12.
AlphAI scores every news story that mentions CLVT with an AI model for sentiment and relevance, and aggregates insider trades from CLARIVATE PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Veinstein Bar (President, A&G) sold 254,558 shares of CLARIVATE PLC (CLVT) at $2.13 ($0.54M total) on 2026-11-18 under a Rule 10b5-1 trading plan.
Clarivate Plc (CLVT) reported a shift to AI-led, subscription-based products, aiming for 10%-15% FY 2027 free cash flow growth and debt reduction. Management targets margin maintenance while driving retention and new business growth, according to a conference transcript.
Clarivate (CLVT) integrated Derwent patent and Darts-ip litigation data into Claude via IPOne, adding to existing CompuMark trademark data. The move expands IP intelligence distribution, but no financial details or impact were disclosed.
Clarivate Plc (CLVT) announced pricing terms for its cash tender offers to purchase certain outstanding debt securities. The company is offering to buy back its 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029, with a total consideration of $979.08 and $928.75 per $1,000 principal amount, respectively. The offers are subject to a $500 million cap and other conditions.
Goldman Sachs kept its Neutral rating on Clarivate but reduced its price target by 11.5% to $2.30, suggesting an 8.5% upside from the Nov 4 close of $2.12.
Jefferies raised its price target on Clarivate (NYSE:CLVT) to $2.25, citing improved annual contract value but noting slower organic revenue growth. The company reported Q3 2026 earnings, beating EPS estimates but missing revenue targets. Clarivate maintains a 68% gross profit margin and expects continued ACV growth. Stifel reiterated a Buy rating with a $5.00 target, citing strong IP unit performance and AI-driven business growth.
Stifel reiterated a Buy rating and $5.00 price target for Clarivate (NYSE:CLVT) after its IP unit showed 1% organic growth and positive ACV growth. Clarivate expects 2% organic growth in Q4 2026 and 9-18% free cash flow growth in 2027. The stock rose 24% intraday. Q3 2026 earnings beat estimates at $0.21 per share, but revenue missed at $481.6M.
Clarivate Plc (CLVT) announced cash tender offers to purchase its 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029, with a total cap of $500M. The offers expire on Nov. 10, 2026, and are subject to conditions. Citigroup is the dealer manager.
Clarivate (CLVT) reported Q3 earnings, highlighting 1% growth in recurring organic revenue and positive ACV growth. The company cited a U.S. Patent and Trademark Office selection and plans for an AI-native IP platform, IPOne. Margins expanded by 300 basis points, and the company updated its 2026 outlook, excluding divested businesses. CLVT expects $1.965B-$1.985B in revenue and $865M-$885M in adjusted EBITDA.
Clarivate (CLVT) completed the sale of its Life Sciences & Healthcare segment in Q3 2026, ahead of schedule. The company anticipates 10%-15% free cash flow growth by 2027. CEO Matti Shem Tov highlighted this as a major milestone in the company's transformation.